T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors

Cancer Gene Therapy

Volumn 7, Issue 8, 2000, Pages 1127-1134

  Patel, Salil D ^a   Moskalenko, Marina ^a   Tian, Tina ^a   Smith, Douglas ^a   McGuinness, Ryan ^a   Chen, Lili ^a   Winslow, Genine A ^a   Kashmiri, Syed ^b   Schlom, Jeffrey ^b   Stanners, Clifford P ^b   Finer, Mitchell H ^c   McArthur, James G ^a  

^a CELL GENESYS INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Bispecific immune receptors; Chimeric immune receptors; Gene therapy; Immunotherapy; T cell receptors

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CHIMERIC PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECEPTOR SUBUNIT; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANTIGEN BINDING; ARTICLE; CANCER CELL DESTRUCTION; CONTROLLED STUDY; CYTOLYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOTHERAPY; LIGAND BINDING; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; VIRUS ENVELOPE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0033846441     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700213     Document Type: Article

References (29)

1. Spontaneous mutation rates of tumorigenic and nontumorigenic Chinese hamster embryo fibroblast cell lines
2. Gene amplification: An example of accelerated evolution in tumorigenic cells
3. Rapid evolution of RNA viruses
4. Evolution of cancer genes as a mutation-driven process
5. Forward mutation rate of human immunodeficiency virus type 1 in a T lymphoid cell line
6. Is HIV unique or merely different?
7. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites
8. + T cells by primary HIV-1 infection: Potential mechanism of vaccine failure
9. The antiretrovirus drug 3'-azido-3'-deoxythymidine increases the retrovirus mutation rate
10. Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen
11. Generation of human monoclonal antibodies to human immunodeficiency virus
12. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies
13. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49
14. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques
15. TAG-72 as a tumor marker
16. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells
17. + T lymphocytes armed with universal T-cell receptors
18. Anti-tumor activity of human T cells expressing the CC49-ζ chimeric immune receptor
19. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal human adult tissues
20. Specificity of anti-carcinoembryonic antigen monoclonal antibodies and their effects on CEA-mediated adhesion
21. Isolation and characterization of full-length functional cDNA clones for human carcinoembryonic antigen
22. The impact of chimeric T cell receptor structure on T cell activity
23. Kat: A high efficiency retroviral transduction system for primary human lymphocytes
24. Use of simian virus 40 replication to amplify Epstein-Barr virus shuttle vectors in human cells
25. Characterization of cell lines showing growth control isolated from both the wild type and a leucyl-tRNA synthetase mutant of Chinese hamster ovary cells
26. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding
27. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
28. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones
29. Systematic T cell-independent tumor immunity after transplantation of universal receptor-modified bone marrow into SCID mice